Molecular Epidemiology of SARS-CoV-2 and Correlation of its Clinical Severity with Different Biochemical Parameters: A Retrospective Study DOI Creative Commons
Maria Bibi, Braira Wahid,

Syed Sib tul Hassan Shah

и другие.

BioScientific Review, Год журнала: 2024, Номер 6(1), С. 70 - 80

Опубликована: Май 9, 2024

Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an infectious disease that was first identified in December 2019 Wuhan, the capital of China's Hubei province. Since then, it has spread globally, resulting ongoing SARS-CoV-2 pandemic. In Pakistan, over 1.5 million cases have been reported since February 2020 (when case reported). Method This retrospective study conducted by classifying data 136 patients into three groups, namely asymptomatic (n = 84), mild 36), and severe 16). The analyzed using IBM SPSS (version 21). Results Age gender showed a non-significant relationship with SARS-CoV-2. Biochemical markers D-DIMER, FERRITIN, CRP, PT significant results p-values 0.001, 0.048, 0.009, respectively (p<0.05). On contrary, APTT (p= 0.146). Conclusion It concluded biochemical parameters seen as best prediction to gauge infection severity. Furthermore, this research established correlation severity also highlighted use these biomarkers diagnostic therapeutic biomarkers.

Язык: Английский

Therapeutic antibodies and alternative formats against SARS-CoV-2 DOI Creative Commons
Rahel R. Winiger, Laurent Perez

Antiviral Research, Год журнала: 2024, Номер 223, С. 105820 - 105820

Опубликована: Фев. 1, 2024

The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines and therapeutics to confront infection, virus remains threat. ancestor viral strain has evolved into several variants concern, with Omicron variant now having many distinct sublineages. Consequently, most available antibodies targeting spike went obsolete thus new therapies or therapeutic formats are needed. In this review we focus on antibody targets, provide an overview progress made so far, describe novel being explored, lessons learned from that can enhance preparedness.

Язык: Английский

Процитировано

3
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity DOI Creative Commons
Zhaohui Cai, Raj Kalkeri, Mi Wang

и другие.

Microorganisms, Год журнала: 2024, Номер 12(6), С. 1201 - 1201

Опубликована: Июнь 14, 2024

The evaluation of coronavirus disease 2019 (COVID-19) vaccine immunogenicity remains essential as the severe acute respiratory syncytial virus 2 (SARS-CoV-2) pandemic continues to evolve and additional variants emerge. Neutralizing antibodies are a known correlate protection for SARS-CoV-2 vaccines. A pseudovirus neutralization (PNT) assay was developed validated at Novavax Clinical Immunology Laboratories allow detection neutralizing in clinical trial sera. PNT precise, accurate, linear, specific measuring titers human serum ancestral strain Omicron subvariants BA.5 XBB.1.5, with an overall geometric coefficient variation ≤43.4%, percent relative bias within expected range −60% 150%, linearity value R2 > 0.98 all three strains. This will be useful analysis samples assess immunogenicity. Future work focus on modifying emerging variants, including XBB.1.16, EG.5.1, BA.2.86, any other that emerge ongoing pandemic.

Язык: Английский

Процитировано

3
Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116) DOI
Qiuyu Cao, Yi Ding, Yu Xu

и другие.

Frontiers of Medicine, Год журнала: 2023, Номер 17(6), С. 1068 - 1079

Опубликована: Дек. 1, 2023

Язык: Английский

Процитировано

7
Prompt-engineering enabled LLM or MLLM and instigative bioinformatics pave the way to identify and characterize the significant SARS-CoV-2 antibody escape mutations DOI
Chiranjib Chakraborty, Manojit Bhattacharya, Soumen Pal

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер unknown, С. 138547 - 138547

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

2
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China DOI

Pulin Li,

Ling Huang, Rui Han

и другие.

Expert Review of Anti-infective Therapy, Год журнала: 2024, Номер 22(6), С. 469 - 477

Опубликована: Фев. 1, 2024

Background Since December 2022, the Omicron variant has led to a widespread pandemic in China. The study was explore safety and effectiveness of Paxlovid for treatment coronavirus disease 2019 (COVID-19).

Язык: Английский

Процитировано

2
Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2 DOI Creative Commons
Philipp Girl, Heiner von Buttlar,

Enrico Mantel

и другие.

Vaccines, Год журнала: 2024, Номер 12(5), С. 515 - 515

Опубликована: Май 9, 2024

The SARS-CoV-2 virus has infected more than 660 million people and caused nearly seven deaths worldwide. During the pandemic, a number of vaccines were rapidly developed, several are currently licensed for use in Europe. However, optimization vaccination regimens is still ongoing, particularly with regard to booster vaccinations. At same time, emergence new variants poses an ongoing challenge vaccine efficacy. In this study, we focused on comparative analysis neutralization capacity vaccine-induced antibodies against four different concern (i.e., Alpha, Beta, Delta, Omicron) after two three doses COVID-19 vaccine. We able show that both (prime/boost) (prime/boost/boost) vaccinations elicit highly variable levels neutralizing antibodies. addition, did not observe significant difference antibody also observed decrease susceptibility all but one contrast, breakthrough infection between second third results overall higher concomitant improved variants. Titer remained across cohort common trend was observed. This may be due fact at time based exclusively wild-type SARS-CoV-2, whereas infections by Overall, our data demonstrate importance (booster) vaccinations, emphasize need continued adaptation induce protective immune response order prepared future (seasonal) outbreaks.

Язык: Английский

Процитировано

2
Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77 DOI

Haihai Jiang,

Wen Li, Xuelan Zhou

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 276, С. 133706 - 133706

Опубликована: Июль 7, 2024

Язык: Английский

Процитировано

2
Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera DOI Creative Commons
Petros Eliadis,

Annie Mais,

Alexandros Papazisis

и другие.

Vaccines, Год журнала: 2024, Номер 12(8), С. 914 - 914

Опубликована: Авг. 13, 2024

Since the initiation of COVID-19 pandemic, there has been a need for development diagnostic methods to determine factors implicated in mounting an immune response against virus. The most promising indicator suggested be neutralizing antibodies (nAbs), which mainly block interaction between Spike protein (S) SARS-CoV-2 and host entry receptor ACE2. In this study, we aimed develop optimize conditions competitive ELISA measure serum titer, using recombinant trimeric modified have six additional proline residues (S(6P)-HexaPro) h-ACE2. results our surrogate Virus Neutralizing Assay (sVNA) were compared commercial sVNT (cPass, Nanjing GenScript Biotech Co., City, China), serially diluted sera from vaccinees, high correlation ID

Язык: Английский

Процитировано

2
The impact of COVID-19 on cancer patients DOI
Demi Wekking, Thilini H. Senevirathne, Josie Pearce

и другие.

Cytokine & Growth Factor Reviews, Год журнала: 2023, Номер 75, С. 110 - 118

Опубликована: Ноя. 30, 2023

Язык: Английский

Процитировано

6
Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals DOI Creative Commons
Tatjana Vilibić‐Čavlek, Vladimir Stevanović,

Snježana Kovač

и другие.

Antibodies, Год журнала: 2023, Номер 12(4), С. 61 - 61

Опубликована: Сен. 25, 2023

Serological diagnosis of COVID-19 is complex due to the emergence different SARS-CoV-2 variants.164 serum samples from (I) patients who recovered (n = 62) as well (II) vaccinated individuals 52) and (III) were infected with variants after vaccination 50) included. All tested using EIA (binding antibodies) a virus neutralization test (VNT) Wuhan strain (NT antibodies). Group III was further VNT Alpha/Delta/Omicron strains.The highest antibody index (AI) observed in (median AI 50, IQR 27-71) lowest 19, 8-48). Similarly, NT titer 128; 32-256) compared 32, 4-128) 8-64). The correlation between strongly positive moderately COVID-19. No significant In Alpha Delta, positivity rate for Omicron variant (85.0%/83.3%). Patients showed 32) Wuhan/Delta (64/128). Delta had 32), Wuhan/Alpha similar titers Delta/Wuhan (128) higher (256).The cross-immunity Alpha/Delta variants.

Язык: Английский

Процитировано

4